Search Clinical Trials in the European Union
>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1341-1360 of 1,743 trials
Kidney Transplant>2 yearsMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementNephrology
Cutibacterium acnes Infection in Shoulder Arthroplasty>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesDermatologyInfectious DiseasesOrthopedics and Traumatology
Women's Infertility>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesPartially RemoteCardiologyGynecology and Obstetrics
APOL1-mediated Proteinuric Kidney Disease>2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteNephrology
Carotid Artery Atherosclerosis>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyNeurology
Polypoidal Choroidal Vasculopathy>2 yearsMonitoring phase (IV)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOphthalmology
Transthyretin Cardiac Amyloidosis>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCardiologyInternal Medicine
Stage II/III Colorectal Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesOncology
Acute Heart Failure>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCardiologyInternal Medicine
Non-small cell lung cancer>2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology
Pulmonary Hypertension>2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementCardiologyInternal Medicine
Prosthetic Joint Infection>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOrthopedics and TraumatologyOtolaryngology
Patients with External Ventricular Drain>2 yearsSafety phase (I)No PlaceboStandard MedicinesInfectious DiseasesPediatrics
HIV Disease>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesInfectious Diseases
Histiocytic Cell Proliferation>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPediatrics
Congenital Antithrombin Deficiency>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesGynecology and ObstetricsHematologyInternal Medicine